

ICH GWAS Monthly Newsletter

Issue 6 - May 2009



Due to impending grant deadlines
the next ICH GWAS Conference Call scheduled for:

Tuesday, May 19th 2009
10-11 am, Eastern USA time



WILL BE CANCELED

Dates for future ICH GWAS Conference Call
will be discussed at the ISGC Meeting in June



In this issue:

Recruitment Updates

2

Enrollment status for ICH GWAS
participating sites recruiting prospectively
and retrospectively

Spotlight: Article

4

Validating, augmenting and refining
genome-wide association signals.

This is the sixth issue of the monthly newsletter for the ICH GWAS Study Group. This newsletter is meant to be a tool to keep investigators participating in the ICH GWAS updated on all aspects of this project, including phenotyping, genotyping, data analysis and logistics.

The newsletter will be sent out to participants on the 15th of each month (or nearest workday) as an email attachment from the Program Manager at the Coordinating Center.

If you want to add topics relevant to all investigators involved in the ICH GWAS to the next newsletter, or you'd like to give general feedback to the Newsletter Design Team please contact:

[Lynelle Cortellini](mailto:lcortellini@partners.org)
(lcortellini@partners.org).

ICH GWAS Monthly Newsletter Issue 5 - April 2009

Recruitment Updates

Sites recruiting prospectively as part of GOCHA

Study site	Period	Warfarin		Non Warfarin		Total
		Case	Control	Case	Control	
Mass General Hospital	February 2009	2	4	5	-	11
	March 2009	1	2	5	0	8
	April 2009	2	2	3	0	7
University of Michigan	February 2009	1	2	1	1	5
	March 2009	-	3	1	2	6
	April 2009	-	-	1	-	1
University of Virginia	February 2009	-	-	-	-	-
	March 2009	-	2	2	25	29
	April 2009	-	-	1	3	4
Mayo Clinic - Jacksonville	February 2009	-	-	1	-	1
	March 2009	-	-	2	-	2
	April 2009	-	-	1	-	1
University of Florida	February 2009	-	-	-	-	-
	March 2009	-	-	-	1	1
	April 2009	-	-	1	-	1
Beth Israel Deaconess Medical Center	February 2009	-	5	1	1	7
	March 2009	-	-	1	1	2
	April 2009	-	-	-	-	-
Totals		6	20	26	34	86

ICH GWAS Monthly Newsletter Issue 5 - April 2009

Sites recruiting prospectively as part of ICH GWAS

Principal Investigator		Institution	Country of Origin	Status
Last Name	First Name			
Majersik	Jennifer	University of Utah	US	Joining
Thjis	Vincent	Leuven	Belgium	Joining
Slowik	Agnieszka	Jagiellonian University, Krakow	Poland	Joined
Schmidt	Reinhold	Medical University Graz	Austria	Joined
Dichgans	Martin	Munich	Germany	Joined

Sites recruiting retrospectively as part of ICH GWAS

Principal Investigator		Institution	Country of Origin	Number of Cases	Number of Controls	Samples received by Genotyping Center
Last Name	First Name					
Lindgren	Arne	University Hospital, Lund	Sweden	250	250	
Markus	Hugh	St. George's, University of London	UK	200	200	
Melander	Olle	Malmo University Hospital	Sweden	100	300	
Montaner	Joan	Vall d'Hebron Hospital	Spain	185	270	
Roquer	Jaume	Hospital del Mar	Spain	200	200	
Schmidt	Reinhold	Medical University Graz	Austria	42	400	
Slowik	Agnieszka	Jagiellonian University	Poland	350	430	Yes

Data presented in the table above are estimates of the number of samples each participating center has pledged to provide for the ICH GWAS. Actual numbers of samples analyzed will vary depending on DNA and phenotype quality.

For further info on this topic please contact:

Alessandro Biffi, M.D.

abiffi@partners.org



Spotlight: Article

Ioannidis JP, Thomas G, Daly MJ

Validating, augmenting and refining genome-wide association signals.

Nat Rev Genet. 2009 May;10(5):318-29

ABSTRACT

Studies using genome-wide platforms have yielded an unprecedented number of promising signals of association between genomic variants and human traits. This Review addresses the steps required to validate, augment and refine such signals to identify underlying causal variants for well-defined phenotypes. These steps include: large-scale exact replication across both similar and diverse populations; fine mapping and resequencing; determination of the most informative markers and multiple independent informative loci; incorporation of functional information; and improved phenotype mapping of the implicated genetic effects. Even in cases for which replication proves that an effect exists, confident localization of the causal variant often remains elusive.